CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2012--
Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells, announced presentations at several upcoming
investment conferences. The conference and Verastem presentation details
are as follows:
-
14th Annual BIO CEO & Investor Conference at 2:00pm ET on
Monday, February 13, 2012 at the Waldorf Astoria Hotel in New York
City.
-
Leerink Swann 2012 Global Healthcare Conference on Thursday, February
16, 2012 at 8:00 am ET at the Waldorf Astoria Hotel in New York City.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells. Cancer stem cells are an underlying cause
of tumor recurrence and metastasis. Verastem is translating discoveries
in cancer stem cell research into new medicines for the treatment of
major cancers such as breast cancer.
Forward-looking statements:
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Source: Verastem, Inc.
Verastem, Inc.
Lacy Roosevelt, 617-520-7052
lroosevelt@webershandwick.com
